Theravance Story

Theravance Inc -- USA Stock  

 9.81  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for Theravance. But even though we do not provide professional-grade financial sentiment analysis on Theravance Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Theravance. Also please take a look at World Market Map.
Glaxo-Innoviva Triple Combo Inhaler Positive in Phase III
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that its once-daily single inhaler triple therapy - Trelegy Ellipta - met primary endpoint in a phase III IMPACT study, showing ... GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing ... - Business Wire Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of ... - Markets Insider

Read More...   

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for Theravance

Its time to give a fresh look to Innoviva, Inc. and Tenet Healthcare
Brokerage houses, on average, are recommending investors to sell Innoviva, Inc. shares projecting a 12.4 target price.
over three weeks ago at 
Theravance Biopharma, Inc. Receives Sell Rating from Robert W. Baird
StockNewsTimesTheravance Biopharmas Buy Rating Reiterated at Cantor Fitzgerald The Ledger GazetteTheravance Biopharma Inc has analysts on the Bullish side this week. Weekly RegisterSEC FORM 4 - SEC.govFull coverage
over a month ago at 
Innoviva, Inc. Holdings Boosted by TIAA CREF Investment Management LLC
patch News
Innoviva logo TIAA CREF Investment Management LLC boosted its stake in shares of Innoviva, Inc. by 38.9 percent during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. Aquinox Pharmaceuticals versus Innoviva Head to Head Review - TrueBlueTribune Innoviva Inc has been downgraded to Hold in a statement by ... - Breaking Finance News

Did you try this?

Run CEO Directory Now

CEO Directory

Screen CEOs from public companies around the world
Hide  View All  NextLaunch CEO Directory

Price to Book

Price to Book Comparative Analysis
Theravance is currently under evaluation in price to book category among related companies. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.